GlassScriptPhysician profile
Shannon Lea Bedja
NPI 1750632949
$3,385.93
in general payments reported to CMS, 2019-2025
23 companies · $428 in 2025
The $428 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $192 · 2022: $991 · 2023: $1,430 · 2024: $345 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,106 · Education: $97.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,106.13 |
| Education | $97.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $994.41 | 2021-2025 | Fasenra, Breztri, Bevespi Aerosphere |
| Jazz Pharmaceuticals INC. | $417.87 | 2022-2025 | |
| Glaxosmithkline, LLC. | $261.43 | 2022-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.65 | 2021-2023 | Stiolto Respimat, Ofev, Spiriva Respimat |
| Amgen INC. | $203.34 | 2023-2024 | Tezspire |
| Electromed, INC. | $198.43 | 2021-2023 | Smartvest |
| Actelion Pharmaceuticals US, INC. | $149.00 | 2022-2023 | Opsumit, Uptravi |
| Regeneron Healthcare Solutions, INC. | $96.93 | 2023 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $95.68 | 2022-2023 | Glassia |
| Body Vision Medical INC. | $92.62 | 2023 | Lungvision |
| Philips North America LLC | $90.86 | 2022-2023 | |
| Genzyme Corporation | $87.57 | 2021-2023 | |
| Mylan Specialty L.P. | $71.33 | 2021-2023 | Yupelri |
| Insmed, INC. | $63.91 | 2022-2025 | Brinsupri |
| Axsome Therapeutics, INC. | $61.15 | 2022-2023 | Sunosi |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $53.28 | 2022 | |
| Covis Pharma Gmbh | $50.00 | 2022-2023 | |
| Harmony Biosciences LLC | $48.21 | 2022-2023 | Wakix |
| Genentech USA, INC. | $48.07 | 2022-2023 | Xolair |
| Grifols USA, LLC | $36.35 | 2023-2025 | Prolastin-C Liquid |
| Resmed Corp | $22.23 | 2023 | |
| Janssen Pharmaceuticals, INC | $14.26 | 2022 | |
| Pfizer INC. | $12.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Bedja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.